Novel has an aggressive pipeline forecasting 10 to 12 ANDA approvals and product launches per year. In its first year alone, Novel filed 8 ANDAs with the USFDA. Currently, Novel has identified over 50 drug products which are in various stages of development to be commercialized in the coming years. As a tenacious first-to-file generic comapany, Novel is continuously pursuing first-to-file & first-to-market opportunities and to date has been awarded 5 first-to-files while awaiting 2 more.

Novel currently has over 20 ANDAs with the USFDA. 5 of those applications have been approved and 3 have received tentative approvals. To supplement its considerable in-house R&D capabilities, Novel has acquired 8 additional ANDAs from other firms for manufacturing and marketing.